|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Laboratory markers in ulcerative colitis: Current insights and future advances显示文摘Ulcerative colitis(UC)and Crohn’s disease(CD)are the major forms of inflammatory bowel diseases(IBD)in man.Despite some common features,these forms can be distinguished by different genetic predisposition,risk factors and clinical,endoscopic and histological characteristics.The aetiology of both CD and UC remains unknown,but several evidences suggest that CD and perhaps UC are due to an excessive immuneresponse directed against normal constituents of the intestinal bacterial flora.Tests sometimes invasive are routine for the diagnosis and care of patients with IBD.Diagnosis of UC is based on clinical symptoms combined with radiological and endoscopic investigations.The employment of non-invasive biomarkers is needed.These biomarkers have the potential to avoid invasive diagnostic tests that may result in discomfort and potential complications.The ability to determine the type,severity,prognosis and response to therapy of UC,using biomarkers has long been a goal of clinical researchers.We describe the biomarkers assessed in UC,with special reference to acute-phase proteins and serologic markers and thereafter,we describe the new biological markers and the biological markers could be developed in the future:(1)serum markers of acute phase response:The laboratory tests most used to measure the acute-phase proteins in clinical practice are the serum concentration of C-reactive protein and the erythrocyte sedimentation rate.Other biomarkers of inflammation in UC include platelet count,leukocyte count,and serum albumin and serum orosomucoid concentrations;(2)serologic markers/antibodies:In the last decades serological and immunologic biomarkers have been studied extensively in immunology and have been used in clinical practice to detect specific pathologies.In UC,the presence of these antibodies can aid as surrogate markers for the aberrant host immune response;and(3)future biomarkers:The development of biomarkers in UC will be very important in the future.The progress of molecular biology tools(microarrays,proteomics and nanotechnology)have revolutionised the field of the biomarker discovery.The advances in bioinformatics coupled with cross-disciplinary collaborations have greatly enhanced our ability to retrieve,characterize and analyse large amounts of data generated by the technological advances.The techniques available for biomarkers development are genomics(single nucleotide polymorphism genotyping,pharmacogenetics and gene expression analyses)and proteomics.In the future,the additionof new serological markers will add significant benefit.Correlating serologic markers with genotypes and clinical phenotypes should enhance our understanding of pathophysiology of UC. | Michele Cioffi Antonella De Rosa Rosalba Serao Ilaria Picone Maria Teresa Vietri | 2015 | World Journal of Gastrointestinal Pathophysiology2015，6，1： | 14 |
| 2 | Epigenetic Reprogramming in Atherosclerosis显示文摘 | Vincenzo Grimaldi Maria Teresa Vietri Concetta Schiano Antonietta Picascia Maria Rosaria De Pascale Carmela Fiorito Amelia Casamassimi Claudio Napoli | 2015 | Current Atherosclerosis Reports2015，，2： | 2 |
| 3 | Serum anti-p53 antibodies in lung cancer:comparison with established tumor markers显示文摘 | CIOFFI M VIETRI M T GAZZERRO P | 2001 | Lung Cancer2001，33，： | 1 |
| 4 | Identification and characterization of a trans-activator involved in the regulation of encapsulation by Bacillus anthracis 显示文摘 | Vietri N J Marrero R Hoover T A | 1995 | Gene1995，152，1： | 1 |
| 5 | Monitoring of in- jection molding of thermoplastics : Average solidification pres- sure as a key parameter for quality control 显示文摘 | SPERANZA V VIETRI U PANTANI R | 2011 | Macromol Res2011，19，6： | 1 |
| 6 | CYP17 and CYP19 gene polymorphisms in women affected with endometriosis 显示文摘 | Vietri MT Cioffi M Sessa M | 2009 | FertilSteril2009，92，5： | 1 |
| 7 | Serum anti-p53 antibodies in lung cancer:comparison with established tumor markers显示文摘 | Cioffi M Vietri MT Cazzerro P | 2001 | Lung Cancer2001，33，23： | 1 |
| 8 | Serum anti-p53 antibodies in lung cancer: comparison with established tumor markers显示文摘 | Cioffi M Vietri M T Gazzerro P | 2001 | Lung Cancer2001，33，23： | 1 |
| 9 | Correlations in the quasi-periodic oscillation frequencies of low-mass X-ray binaries and the relativistic precession model显示文摘 | Stella L Vietri M Morsink S M | | 0，，： | 1 |
| 10 | Outpatient repair for inguinal hernia in elderly patients:Still a challenge 显示文摘 | Palumbo P Amatucci C Vietri F | 2014 | Int J Surg2014，24，2： | 1 |
| 11 | CYP17 and CYP19 gene poly- morphisms in women affected with endometriosis 显示文摘 | Vietri MT Cioffi M Sessa M | 2009 | Fertil Steril2009，92，5： | 1 |
| 12 | CYP17 and CYP19 gene polymerphisms in women affected with endometriesis显示文摘 | Vietri MT Cioffi M Seasa M | 2009 | Fertil Steril2009，92，5： | 1 |
| 13 | IVS4-14 A/G and IVS4-73C/T polymorphisms in OLR1 gene in patients with ischemic cerebrovascular diseases显示文摘 | Vietri MT Molinari AM Boggia M | 2010 | Genet Test Mol Biomarkers2010，14，1： | 1 |
| 14 | Cyclic k-cycle systems of order 2kn+k:a solution of the last open cases显示文摘 | Vietri A | 2004 | Combin Designs(S1063-8539)2004，12，： | 1 |
| 15 | Are some BL Lac objects artefacts of gravitational lensing显示文摘 | Ostriker J P Vietri M | 1985 | Nat1985，318，： | 1 |
| 16 | Serum anti-p53 antibodies in lung cancer: comparison with established tumor makers显示文摘 | Cioffi M Vietri M Gazzerro P | 2001 | Lung Cancer2001，33，23： | 1 |
| 17 | Arg72Pro p53pol ymor phi sm in It a l i an women:no a s soc i at ion wi thendometriosis显示文摘 | Vietri MT Molinari AM Iannella I | 2007 | Fertil Steril2007，88，5： | 1 |
| 18 | Nanofilled epoxy adhesive for structural aeronautic materials显示文摘 | U. Vietri L. Guadagno M. Raimondo L. Vertuccio K. Lafdi | 2014 | Composites Part B2014，，： | 1 |
| 19 | A gamma ray burst with small contamination 显示文摘 | Vietri M Stella L | 1998 | ApJ1998，507，： | 1 |
| 20 | Serum anti-p53 antibodies in lung cancer: comparison with established minor markers 显示文摘 | Cioffi M Vietri MT Cazzerro P | 2001 | Lung Cancer2001，33，23： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员